Azzad Asset Management Inc. ADV Invests $552,000 in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Azzad Asset Management Inc. ADV purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 16,847 shares of the specialty pharmaceutical company's stock, valued at approximately $552,000.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock valued at $222,411,000 after buying an additional 22,852 shares during the period. Geode Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock valued at $54,633,000 after purchasing an additional 28,517 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Supernus Pharmaceuticals by 9.2% during the fourth quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after buying an additional 95,777 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Supernus Pharmaceuticals by 5.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock valued at $27,242,000 after purchasing an additional 40,968 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Supernus Pharmaceuticals by 18.3% during the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after buying an additional 110,867 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 1.9%

NASDAQ:SUPN traded up $0.63 on Thursday, hitting $32.96. The company's stock had a trading volume of 583,113 shares, compared to its average volume of 485,204. The stock has a fifty day moving average of $32.09 and a two-hundred day moving average of $34.27. Supernus Pharmaceuticals, Inc. has a one year low of $25.55 and a one year high of $40.28. The firm has a market capitalization of $1.85 billion, a P/E ratio of 29.69 and a beta of 0.71.

Analysts Set New Price Targets

A number of research firms have issued reports on SUPN. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.